- Home
- CMP vs ANAB Comparison
CMP vs ANAB Comparison
Compare CMP & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMP | ANAB |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2003 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CMP | ANAB |
|---|---|---|
| Price | $28.36 | $51.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $21.50 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 748.5K | 503.5K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.73 | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.29 | $52.14 |
| P/E Ratio | $40.16 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $16.40 | $17.11 |
| 52 Week High | $34.50 | $73.30 |
Technical Indicators
Market Signals| Indicator | CMP | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 34.77 |
| Support Level | $27.30 | $43.75 |
| Resistance Level | $32.39 | $57.70 |
| Average True Range (ATR) | 1.33 | 2.50 |
| MACD | -0.51 | -0.49 |
| Stochastic Oscillator | 7.47 | 13.45 |
Price Performance
Historical ComparisonAbout CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).